Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus activated allogeneic NK cells for relapsed/refractory multiple myeloma
IRCT20230801058996N9Phase 2Not yet recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Feb 2027
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, fludarabine and cyclophosphamide in multiple myeloma (MM), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Adverse effects during or after combination therapy with allogeneic NK cells and daratumumab and Response to treatment based on IMWG criteria. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
daratumumabfludarabinecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on IRCT20230801058996N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230801058996N9.